REGULATORY & LEGAL

The Compounding Litigation Map: Every Novo Nordisk and Lilly Lawsuit Against GLP-1 Compounders

Published June 2026 · Sources verified June 2026

The legal campaign against GLP-1 compounders is multi-pronged: manufacturer lawsuits alleging trademark infringement and impurities, FDA enforcement actions through warning letters and proposed rulemaking, DOJ referrals for investigation, and state medical board disciplinary actions against prescribers. This article tracks the key actions.

455+

Adverse Events (Sema)

320+

Adverse Events (Tirz)

80+

FDA Warning Letters

DOJ

Hims & Hers Referral

Novo Nordisk's Legal Campaign

Novo Nordisk has been the most aggressive litigant, filing suits against multiple compounding pharmacies that marketed compounded semaglutide products. Key allegations include:¹

Trademark infringement: Using "Ozempic" and "Wegovy" names to market compounded products
Product quality: Allegations that some compounded semaglutide contained impurities up to 86%
False advertising: Claims that compounded versions are "identical" or "equivalent" to FDA-approved products

The Hims & Hers DOJ Referral

On February 6, 2026, the HHS General Counsel announced a referral of Hims & Hers to the Department of Justice for investigation. The same day, Hims & Hers had launched a compounded oral semaglutide product marketed as an alternative to Wegovy's newly approved pill. The timing was not coincidental.^2,3

FDA Enforcement Timeline

Date	Action	Impact
Feb 2025	Semaglutide shortage resolved; enforcement discretion period began	503A pharmacies lost shortage exemption
Mar 2025	Tirzepatide enforcement discretion ended for 503A	503A compounding of tirz copies effectively barred
May 2025	503B enforcement discretion for semaglutide ended	503B outsourcing facilities barred
2025–2026	80+ warning letters to compounders and telehealth platforms	Targeted claims of equivalence to FDA-approved products
Apr 30, 2026	FDA proposed excluding sema/tirz/lira from 503B Bulks List	Would permanently bar 503B compounding
June 29, 2026	Public comment period closes	Final rule expected to follow

The Safety Data Driving Enforcement

The FDA's enforcement posture is supported by adverse event data. As of early 2025, the agency had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide. Many involved dosing errors from patients self-administering improperly compounded preparations, contamination, and variable potency.^4,5

⚠ IMPORTANT CAVEATSAdverse event reports are not proof of causation — they reflect reports submitted, not verified harms. The 455/320 figures should be interpreted in the context of millions of compounded GLP-1 prescriptions dispensed during the shortage period. However, the FDA has no comparable safety signal for FDA-approved GLP-1 formulations at equivalent scale.

The regulatory and legal momentum is moving in one direction. Large-scale GLP-1 compounding is being systematically shut down through courts, rulemaking, and enforcement. The question for patients is not whether compounding will continue at current scale — it won't — but how quickly the transition to brand-name alternatives happens and whether affordable access is preserved.

SOURCES

Novo Nordisk v. various compounders. Multiple federal district courts. 2024-2026.
HHS General Counsel. Referral of Hims & Hers to DOJ. Social media announcement. February 6, 2026.
Polsinelli PC. FDA Tightens the Belt on GLP-1 Compounding. National Law Review. February 10, 2026.
Pharmacy Times. FDA Moves to Permanently Close the Door on Compounded GLP-1s. May 2026.
FDA adverse event reports: 455+ compounded semaglutide, 320+ compounded tirzepatide.